Dear Editor,Pathological neo-vascularization is a hallmark of cancer and several diseases.Accumulating evidence supports the notion that antiangiogenic treatment can abolish tumor angiogenesis to achieve Ion ger disea...Dear Editor,Pathological neo-vascularization is a hallmark of cancer and several diseases.Accumulating evidence supports the notion that antiangiogenic treatment can abolish tumor angiogenesis to achieve Ion ger disease-free survival.Although growth factors and their receptors function as the main drivers in angiogenesis,the involvement of other regulators,e.g.,Cyclooxygenase-2(COX2),^(1) should also be con sidered,especially for managi ng the resista nee to therapies against receptor tyrosine kinases(RTKs).展开更多
Correction to:Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-021-00739-5,published online 03 December 2021 After online publication of the letter1,the author found two images in the supplement...Correction to:Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-021-00739-5,published online 03 December 2021 After online publication of the letter1,the author found two images in the supplement materials were used incorrectly,Additionally,there is an error in the chemical structure of Aiphanol in Figs.1a and 1s that needs to be corrected.The correct data are provided as follows.The key findings of the article are not affected by these corrections.The original article has been corrected.展开更多
基金This study was supported by the National Natural Science Foundation of China(81773219)National Basic Research Program of China(2015CB553906)the PKU-Baidu Fund(2019BD015).
文摘Dear Editor,Pathological neo-vascularization is a hallmark of cancer and several diseases.Accumulating evidence supports the notion that antiangiogenic treatment can abolish tumor angiogenesis to achieve Ion ger disease-free survival.Although growth factors and their receptors function as the main drivers in angiogenesis,the involvement of other regulators,e.g.,Cyclooxygenase-2(COX2),^(1) should also be con sidered,especially for managi ng the resista nee to therapies against receptor tyrosine kinases(RTKs).
文摘Correction to:Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-021-00739-5,published online 03 December 2021 After online publication of the letter1,the author found two images in the supplement materials were used incorrectly,Additionally,there is an error in the chemical structure of Aiphanol in Figs.1a and 1s that needs to be corrected.The correct data are provided as follows.The key findings of the article are not affected by these corrections.The original article has been corrected.
